You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSilodosin
Accession NumberDB06207
TypeSmall Molecule
GroupsApproved
DescriptionSilodosin is an α1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. FDA approved Oct 9, 2008.
Structure
Thumb
Synonyms
KAD 3213
KMD 3213
Rapaflo
Urief
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Rapaflocapsule4 mg/1oralActavis Pharma, Inc.2009-03-23Not applicableUs
Rapaflocapsule4 mg/1oralAvera Mc Kennan Hospital2015-05-01Not applicableUs
Rapaflocapsule8 mg/1oralActavis Pharma, Inc.2009-03-23Not applicableUs
Rapaflocapsule4 mgoralActavis Specialty Pharmaceuticals Co2011-10-26Not applicableCanada
Rapaflocapsule8 mg/1oralPhysicians Total Care, Inc.2010-09-15Not applicableUs
Rapaflocapsule8 mgoralActavis Specialty Pharmaceuticals Co2011-10-26Not applicableCanada
Rapaflocapsule8 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RapilifIpca Urosciences
Silodyx Recordati Industria Chimica e Farmaceutica S.p.A.
UriefWatson Pharmaceuticals Inc.
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICUZ39LUY82
CAS number160970-54-7
WeightAverage: 495.5345
Monoisotopic: 495.234491142
Chemical FormulaC25H32F3N3O4
InChI KeyInChIKey=PNCPYILNMDWPEY-QGZVFWFLSA-N
InChI
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
IUPAC Name
1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide
SMILES
C[[email protected]](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndolecarboxylic acids and derivatives
Direct ParentIndolecarboxamides and derivatives
Alternative Parents
Substituents
  • Indolecarboxamide derivative
  • Benzamide
  • Dialkylarylamine
  • Phenol ether
  • Benzoyl
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Vinylogous amide
  • 1,3-aminoalcohol
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationTreatment for symptomatic relief of benign prostatic hyperplasia
PharmacodynamicsSilodosin is 583 times more selective for human alpha-1A receptors than alpha-1B receptors. It is also 56 times more selective for human alpha-1A receptors than alpha-1D. Silodosin does not prolong the QT interval.
Mechanism of actionBenign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH.
Related Articles
AbsorptionQuickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose). When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: Cmax = 61.6 ± 27.54 ng/mL; Tmax = 2.6 ± 0.90 hours; AUC (0h-24h) = 373 ng•hr/ml. The AUC of its metabolite, KMD3213G, is four times greater than silodosin.
Volume of distribution

49.5 L

Protein binding97% bound to protein
Metabolism

Extensively metabolized in the liver. The main metabolite is generated via glucuronidation (KMD-3213G) by UDP-2B7. Oxidation by alcohol and aldehyde dehydrogenases produces the second major metabolite, KMD-3293. KMD-3213G accumulates in the plasma as it is very hydrophilic. KMD-3213G is also an active metabolite in which it has 50% of silodosin's inhibitory activity. KMD-3293 is inactive. Cytochrome P450 CYP 3A4 also generates some metabolites.

Route of eliminationFecal (54.9%); Renal (33.5%)
Half lifeSilodosin = 13.3 ± 8.07 hours; KMD-3213G = 24 hours;
Clearance

Plasma clearance = 10 L/h

ToxicityMost common adverse reactions (incidence > 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7383
Caco-2 permeable-0.5847
P-glycoprotein substrateSubstrate0.8467
P-glycoprotein inhibitor INon-inhibitor0.5833
P-glycoprotein inhibitor IIInhibitor0.7864
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.8226
CYP450 2D6 substrateNon-substrate0.6362
CYP450 3A4 substrateSubstrate0.6585
CYP450 1A2 substrateNon-inhibitor0.7439
CYP450 2C9 inhibitorNon-inhibitor0.7569
CYP450 2D6 inhibitorNon-inhibitor0.5958
CYP450 2C19 inhibitorNon-inhibitor0.5562
CYP450 3A4 inhibitorInhibitor0.7424
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5723
Ames testNon AMES toxic0.6667
CarcinogenicityNon-carcinogens0.8529
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4845 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.98
hERG inhibition (predictor II)Inhibitor0.8366
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral4 mg/1
Capsuleoral4 mg
Capsuleoral8 mg
Capsuleoral8 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5387603 No1998-12-012018-12-01Us
US5403847 No1992-11-132012-11-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105 - 109°CFDA label
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0111 mg/mLALOGPS
logP2.96ALOGPS
logP3.05ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.87ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area97.05 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity128.92 m3·mol-1ChemAxon
Polarizability49.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Yoshida M, Homma Y, Kawabe K: Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007 Dec;16(12):1955-65. [PubMed:18042003 ]
  2. Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K: Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull. 2007 Jul;30(7):1237-41. [PubMed:17603160 ]
External Links
ATC CodesG04CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (846 KB)
MSDSDownload (479 KB)
Interactions
Drug Interactions
Drug
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Silodosin.
AcetaminophenThe serum concentration of Silodosin can be increased when it is combined with Acetaminophen.
AfatinibThe serum concentration of Silodosin can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Silodosin can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Silodosin can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Silodosin can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Silodosin can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the antihypertensive activities of Silodosin.
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Silodosin.
AmantadineThe serum concentration of Silodosin can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Silodosin can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Silodosin can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Silodosin can be increased when it is combined with Amlodipine.
AmlodipineSilodosin may increase the hypotensive activities of Amlodipine.
AmprenavirThe serum concentration of Silodosin can be increased when it is combined with Amprenavir.
AmrinoneSilodosin may increase the hypotensive activities of Amrinone.
AmsacrineThe serum concentration of Silodosin can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Silodosin can be increased when it is combined with Aprepitant.
ArotinololArotinolol may increase the orthostatic hypotensive activities of Silodosin.
AstemizoleThe serum concentration of Silodosin can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Silodosin can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Silodosin can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Silodosin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Silodosin can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Silodosin can be increased when it is combined with Azelastine.
AzelnidipineSilodosin may increase the hypotensive activities of Azelnidipine.
AzimilideSilodosin may increase the hypotensive activities of Azimilide.
AzithromycinThe serum concentration of Silodosin can be increased when it is combined with Azithromycin.
BarnidipineSilodosin may increase the hypotensive activities of Barnidipine.
BefunololBefunolol may increase the orthostatic hypotensive activities of Silodosin.
BenidipineSilodosin may increase the hypotensive activities of Benidipine.
BenzocaineThe serum concentration of Silodosin can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Silodosin can be increased when it is combined with Bepridil.
BepridilSilodosin may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Silodosin.
BevantololBevantolol may increase the orthostatic hypotensive activities of Silodosin.
BexaroteneThe serum concentration of Silodosin can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Silodosin can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Silodosin.
BoceprevirThe serum concentration of Silodosin can be increased when it is combined with Boceprevir.
BopindololBopindolol may increase the orthostatic hypotensive activities of Silodosin.
BortezomibThe metabolism of Silodosin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Silodosin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Silodosin can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Silodosin can be increased when it is combined with Bromocriptine.
BufuralolBufuralol may increase the orthostatic hypotensive activities of Silodosin.
BupranololBupranolol may increase the orthostatic hypotensive activities of Silodosin.
BuprenorphineThe serum concentration of Silodosin can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Silodosin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Silodosin can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Silodosin can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Silodosin can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Silodosin can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Silodosin can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Silodosin can be increased when it is combined with Carbamazepine.
CarteololCarteolol may increase the orthostatic hypotensive activities of Silodosin.
CarvedilolThe serum concentration of Silodosin can be increased when it is combined with Carvedilol.
CarvedilolSilodosin may increase the antihypertensive activities of Carvedilol.
CaspofunginThe serum concentration of Silodosin can be increased when it is combined with Caspofungin.
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Silodosin.
CeritinibThe serum concentration of Silodosin can be increased when it is combined with Ceritinib.
ChloroquineThe serum concentration of Silodosin can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Silodosin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Silodosin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Silodosin can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Silodosin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Silodosin can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Silodosin can be increased when it is combined with Cilazapril.
CilnidipineSilodosin may increase the hypotensive activities of Cilnidipine.
CimetidineThe serum concentration of Silodosin can be increased when it is combined with Cimetidine.
CinnarizineSilodosin may increase the hypotensive activities of Cinnarizine.
CiprofloxacinThe serum concentration of Silodosin can be increased when it is combined with Ciprofloxacin.
CirazolineSilodosin may decrease the vasoconstricting activities of Cirazoline.
CitalopramThe serum concentration of Silodosin can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Silodosin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Silodosin can be decreased when combined with Clemastine.
ClevidipineSilodosin may increase the hypotensive activities of Clevidipine.
ClofazimineThe serum concentration of Silodosin can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Silodosin can be increased when it is combined with Clomipramine.
ClotrimazoleThe serum concentration of Silodosin can be increased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Silodosin can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Silodosin can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Silodosin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Silodosin can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Silodosin can be increased when it is combined with Crizotinib.
CyclophosphamideThe serum concentration of Silodosin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.
DabrafenibThe serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Silodosin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Silodosin can be increased when it is combined with Dactinomycin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Silodosin.
DarodipineSilodosin may increase the hypotensive activities of Darodipine.
DarunavirThe serum concentration of Silodosin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Silodosin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Silodosin can be increased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Silodosin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Silodosin can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Silodosin can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Silodosin can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Silodosin can be increased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Silodosin can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Silodosin can be increased when it is combined with Diclofenac.
DigoxinThe serum concentration of Silodosin can be increased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Silodosin can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Silodosin can be increased when it is combined with Diltiazem.
DiltiazemSilodosin may increase the hypotensive activities of Diltiazem.
DipyridamoleThe serum concentration of Silodosin can be increased when it is combined with Dipyridamole.
DotarizineSilodosin may increase the hypotensive activities of Dotarizine.
DoxazosinThe serum concentration of Silodosin can be increased when it is combined with Doxazosin.
DoxazosinSilodosin may increase the antihypertensive activities of Doxazosin.
DoxepinThe serum concentration of Silodosin can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Silodosin can be increased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Silodosin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Silodosin can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Silodosin can be increased when it is combined with Dronedarone.
EfavirenzThe serum concentration of Silodosin can be decreased when it is combined with Efavirenz.
EfonidipineSilodosin may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Silodosin can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Silodosin can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Silodosin can be increased when it is combined with Enzalutamide.
EperisoneSilodosin may increase the hypotensive activities of Eperisone.
ErgonovineThe serum concentration of Silodosin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Silodosin can be increased when it is combined with Ergotamine.
ErgotamineSilodosin may decrease the vasoconstricting activities of Ergotamine.
ErythromycinThe serum concentration of Silodosin can be increased when it is combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Silodosin can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the orthostatic hypotensive activities of Silodosin.
EstramustineThe serum concentration of Silodosin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Silodosin can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Silodosin can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Silodosin can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Silodosin can be increased when it is combined with Etravirine.
FelodipineThe serum concentration of Silodosin can be increased when it is combined with Felodipine.
FelodipineSilodosin may increase the hypotensive activities of Felodipine.
FendilineSilodosin may increase the hypotensive activities of Fendiline.
FentanylThe serum concentration of Silodosin can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Silodosin can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Silodosin can be increased when it is combined with Fidaxomicin.
FluconazoleThe serum concentration of Silodosin can be increased when it is combined with Fluconazole.
FlunarizineSilodosin may increase the hypotensive activities of Flunarizine.
FluoxetineThe serum concentration of Silodosin can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Silodosin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Silodosin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Silodosin can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Silodosin can be increased when it is combined with Fluvoxamine.
FosamprenavirThe metabolism of Silodosin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Silodosin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Silodosin can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Silodosin can be increased when it is combined with Fusidic Acid.
GabapentinSilodosin may increase the hypotensive activities of Gabapentin.
GefitinibThe serum concentration of Silodosin can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Silodosin can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Silodosin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Silodosin can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Silodosin can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Silodosin can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Silodosin can be increased when it is combined with Haloperidol.
HydrocortisoneThe serum concentration of Silodosin can be increased when it is combined with Hydrocortisone.
IdelalisibThe serum concentration of Silodosin can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Silodosin can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Silodosin can be increased when it is combined with Imipramine.
IndenololIndenolol may increase the orthostatic hypotensive activities of Silodosin.
IndinavirThe serum concentration of Silodosin can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Silodosin can be increased when it is combined with Indomethacin.
IndoraminSilodosin may increase the antihypertensive activities of Indoramin.
IsavuconazoniumThe serum concentration of Silodosin can be increased when it is combined with Isavuconazonium.
IsradipineSilodosin may increase the hypotensive activities of Isradipine.
IsradipineThe metabolism of Silodosin can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Silodosin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Silodosin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Silodosin can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Silodosin can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Silodosin can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the antihypertensive activities of Silodosin.
LacidipineSilodosin may increase the hypotensive activities of Lacidipine.
LamotrigineSilodosin may increase the hypotensive activities of Lamotrigine.
LansoprazoleThe serum concentration of Silodosin can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Silodosin can be increased when it is combined with Lapatinib.
LercanidipineSilodosin may increase the hypotensive activities of Lercanidipine.
LevofloxacinThe serum concentration of Silodosin can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Silodosin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Silodosin can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Silodosin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Silodosin can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Silodosin can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Silodosin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Silodosin can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Silodosin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Silodosin can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Silodosin can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Silodosin can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Silodosin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Silodosin can be decreased when it is combined with Lumacaftor.
Magnesium SulfateSilodosin may increase the hypotensive activities of Magnesium Sulfate.
ManidipineSilodosin may increase the hypotensive activities of Manidipine.
MaprotilineThe serum concentration of Silodosin can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Silodosin can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Silodosin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Silodosin can be increased when it is combined with Megestrol acetate.
MephentermineSilodosin may decrease the vasoconstricting activities of Mephentermine.
MeprobamateThe serum concentration of Silodosin can be increased when it is combined with Meprobamate.
MetaraminolSilodosin may decrease the vasoconstricting activities of Metaraminol.
MethadoneThe serum concentration of Silodosin can be increased when it is combined with Methadone.
MethoxamineSilodosin may decrease the vasoconstricting activities of Methoxamine.
MetoprololThe serum concentration of Silodosin can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Silodosin can be increased when it is combined with Mibefradil.
MibefradilSilodosin may increase the hypotensive activities of Mibefradil.
MiconazoleThe serum concentration of Silodosin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Silodosin can be increased when it is combined with Midazolam.
MidodrineSilodosin may decrease the vasoconstricting activities of Midodrine.
MifepristoneThe serum concentration of Silodosin can be increased when it is combined with Mifepristone.
MitomycinThe serum concentration of Silodosin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Silodosin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Silodosin can be increased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Silodosin can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Silodosin can be increased when it is combined with Morphine.
NadololNadolol may increase the orthostatic hypotensive activities of Silodosin.
NafcillinThe serum concentration of Silodosin can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Silodosin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Silodosin can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Silodosin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Silodosin can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Silodosin can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Silodosin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Silodosin can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Silodosin can be increased when it is combined with Nicardipine.
NicardipineSilodosin may increase the hypotensive activities of Nicardipine.
NifedipineThe serum concentration of Silodosin can be increased when it is combined with Nifedipine.
NifedipineSilodosin may increase the hypotensive activities of Nifedipine.
NiguldipineSilodosin may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Silodosin can be increased when it is combined with Nilotinib.
NiludipineSilodosin may increase the hypotensive activities of Niludipine.
NilvadipineSilodosin may increase the hypotensive activities of Nilvadipine.
NimesulideSilodosin may increase the hypotensive activities of Nimesulide.
NimodipineSilodosin may increase the hypotensive activities of Nimodipine.
NisoldipineThe serum concentration of Silodosin can be increased when it is combined with Nisoldipine.
NisoldipineSilodosin may increase the hypotensive activities of Nisoldipine.
NitrazepamThe serum concentration of Silodosin can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Silodosin can be increased when it is combined with Nitrendipine.
NitrendipineSilodosin may increase the hypotensive activities of Nitrendipine.
NorethisteroneThe serum concentration of Silodosin can be decreased when it is combined with Norethisterone.
OlaparibThe metabolism of Silodosin can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Silodosin can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Silodosin can be increased when it is combined with Osimertinib.
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Silodosin.
P-NitrophenolThe serum concentration of Silodosin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Silodosin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Silodosin can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Silodosin can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Silodosin can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Silodosin can be increased when it is combined with Paroxetine.
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Silodosin.
PentobarbitalThe metabolism of Silodosin can be increased when combined with Pentobarbital.
PerhexilineSilodosin may increase the hypotensive activities of Perhexiline.
PerindoprilThe serum concentration of Silodosin can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Silodosin can be decreased when it is combined with Phenobarbital.
PhenylephrineSilodosin may decrease the vasoconstricting activities of Phenylephrine.
PhenytoinThe metabolism of Silodosin can be increased when combined with Phenytoin.
PimozideThe serum concentration of Silodosin can be increased when it is combined with Pimozide.
PinaveriumSilodosin may increase the hypotensive activities of Pinaverium.
PindololPindolol may increase the orthostatic hypotensive activities of Silodosin.
Platelet Activating FactorThe serum concentration of Silodosin can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Silodosin can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Silodosin can be increased when it is combined with Posaconazole.
PractololPractolol may increase the orthostatic hypotensive activities of Silodosin.
PravastatinThe serum concentration of Silodosin can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Silodosin can be increased when it is combined with Prazosin.
PrazosinSilodosin may increase the antihypertensive activities of Prazosin.
PrednisoneThe serum concentration of Silodosin can be increased when it is combined with Prednisone.
PregabalinSilodosin may increase the hypotensive activities of Pregabalin.
PrenylamineSilodosin may increase the hypotensive activities of Prenylamine.
PrimidoneThe metabolism of Silodosin can be increased when combined with Primidone.
ProbenecidThe serum concentration of Silodosin can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Silodosin can be increased when it is combined with Progesterone.
PromethazineThe serum concentration of Silodosin can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Silodosin can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Silodosin can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Silodosin can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Silodosin can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Silodosin can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Silodosin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Silodosin can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Silodosin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Silodosin can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Silodosin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Silodosin can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Silodosin can be increased when it is combined with Reserpine.
RifabutinThe metabolism of Silodosin can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Silodosin can be increased when it is combined with Rifampicin.
RifapentineThe metabolism of Silodosin can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Silodosin can be increased when it is combined with Rilpivirine.
RisedronateSilodosin may increase the hypotensive activities of Risedronate.
RitonavirThe serum concentration of Silodosin can be increased when it is combined with Ritonavir.
RolapitantThe serum concentration of Silodosin can be increased when it is combined with Rolapitant.
SaquinavirThe serum concentration of Silodosin can be increased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Silodosin can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Silodosin can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Silodosin can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Silodosin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Silodosin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Silodosin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Silodosin can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Silodosin can be increased when it is combined with Sirolimus.
SorafenibThe serum concentration of Silodosin can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the orthostatic hypotensive activities of Silodosin.
SpironolactoneThe serum concentration of Silodosin can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Silodosin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Silodosin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Silodosin can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Silodosin can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Silodosin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Silodosin can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Silodosin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Silodosin can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Silodosin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Silodosin can be increased when it is combined with Tacrolimus.
TadalafilTadalafil may increase the hypotensive activities of Silodosin.
TamoxifenThe serum concentration of Silodosin can be increased when it is combined with Tamoxifen.
TamsulosinTamsulosin may increase the antihypertensive activities of Silodosin.
Taurocholic AcidThe serum concentration of Silodosin can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Silodosin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Silodosin can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Silodosin can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Silodosin can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Silodosin can be increased when it is combined with Terazosin.
TerazosinSilodosin may increase the antihypertensive activities of Terazosin.
TerfenadineThe serum concentration of Silodosin can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Silodosin can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Silodosin can be increased when it is combined with Testosterone.
TicagrelorThe serum concentration of Silodosin can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Silodosin can be decreased when combined with Ticlopidine.
TimololTimolol may increase the orthostatic hypotensive activities of Silodosin.
TocilizumabThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.
Tolfenamic AcidSilodosin may increase the hypotensive activities of Tolfenamic Acid.
TolvaptanThe serum concentration of Silodosin can be increased when it is combined with Tolvaptan.
TranilastSilodosin may increase the hypotensive activities of Tranilast.
TrazodoneThe serum concentration of Silodosin can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Silodosin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Silodosin can be increased when it is combined with Triflupromazine.
TrimazosinSilodosin may increase the antihypertensive activities of Trimazosin.
TrimethoprimThe serum concentration of Silodosin can be increased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Silodosin can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Silodosin can be increased when it is combined with Troleandomycin.
UdenafilUdenafil may increase the hypotensive activities of Silodosin.
VardenafilVardenafil may increase the hypotensive activities of Silodosin.
VenlafaxineThe serum concentration of Silodosin can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Silodosin can be increased when it is combined with Verapamil.
VerapamilSilodosin may increase the hypotensive activities of Verapamil.
VinblastineThe serum concentration of Silodosin can be increased when it is combined with Vinblastine.
VincristineThe serum concentration of Silodosin can be increased when it is combined with Vincristine.
VinorelbineThe serum concentration of Silodosin can be increased when it is combined with Vinorelbine.
VoriconazoleThe serum concentration of Silodosin can be increased when it is combined with Voriconazole.
XylometazolineSilodosin may increase the hypotensive activities of Xylometazoline.
ZiconotideSilodosin may increase the hypotensive activities of Ziconotide.
ZimelidineThe serum concentration of Silodosin can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Silodosin can be decreased when combined with Ziprasidone.
Food Interactions
  • The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin Cmax by approximately 18 − 43% and AUC by 4 − 49%

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
  2. Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr: Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10. doi: 10.1345/aph.1M320. Epub 2010 Jan 13. [PubMed:20071497 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion. Functions as a floppase that translocates specifically phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular membrane bilayer into the canaliculi of hepatocytes. Translocation of PC makes the biliary phospholipids available for extraction into the canaliculi ...
Gene Name:
ABCB4
Uniprot ID:
P21439
Molecular Weight:
141521.845 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:17 / Updated on September 29, 2016 02:26